Failed	O
degradation	O
of	O
JunB	S-GENE
contributes	O
to	O
overproduction	O
of	O
type	B-GENE
I	I-GENE
collagen	E-GENE
and	O
development	O
of	O
dermal	O
fibrosis	O
in	O
patients	O
with	O
systemic	O
sclerosis	O
.	O


OBJECTIVE	O
:	O
The	O
excessive	O
deposition	O
of	O
extracellular	O
matrix	O
,	O
including	O
type	B-GENE
I	I-GENE
collagen	E-GENE
,	O
is	O
a	O
key	O
aspect	O
in	O
the	O
pathogenesis	O
of	O
connective	O
tissue	O
diseases	O
such	O
as	O
systemic	O
sclerosis	O
(	O
SSc	O
;	O
scleroderma	O
)	O
.	O


To	O
further	O
our	O
understanding	O
of	O
the	O
mechanisms	O
governing	O
the	O
dysregulation	O
of	O
type	B-GENE
I	I-GENE
collagen	E-GENE
production	O
in	O
SSc	O
,	O
we	O
investigated	O
the	O
role	O
of	O
the	O
activator	B-GENE
protein	I-GENE
1	E-GENE
(	O
AP	B-GENE
-	I-GENE
1	E-GENE
)	O
family	O
of	O
transcription	O
factors	O
in	O
regulating	O
COL1A2	S-GENE
transcription	O
.	O


METHODS	O
:	O
The	O
expression	O
and	O
nuclear	O
localization	O
of	O
AP	B-GENE
-	I-GENE
1	E-GENE
family	O
members	O
(	O
c	B-GENE
-	I-GENE
Jun	E-GENE
,	O
JunB	S-GENE
,	O
JunD	S-GENE
,	O
Fra	B-GENE
-	I-GENE
1	E-GENE
,	O
Fra	B-GENE
-	I-GENE
2	E-GENE
,	O
and	O
c	B-GENE
-	I-GENE
Fos	E-GENE
)	O
were	O
examined	O
by	O
immunohistochemistry	O
and	O
Western	O
blotting	O
in	O
dermal	O
biopsy	O
specimens	O
and	O
explanted	O
skin	O
fibroblasts	O
from	O
patients	O
with	O
diffuse	O
cutaneous	O
SSc	O
and	O
healthy	O
controls	O
.	O


Gene	O
activation	O
was	O
determined	O
by	O
assessing	O
the	O
interaction	O
of	O
transcription	O
factors	O
with	O
the	O
COL1A2	S-GENE
enhancer	O
using	O
transient	O
transfection	O
of	O
reporter	O
gene	O
constructs	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
chromatin	O
immunoprecipitation	O
analysis	O
,	O
and	O
RNA	O
interference	O
involving	O
knockdown	O
of	O
individual	O
AP	B-GENE
-	I-GENE
1	E-GENE
family	O
members	O
.	O


Inhibition	O
of	O
fibroblast	O
mammalian	B-GENE
target	I-GENE
of	I-GENE
rapamycin	E-GENE
(	O
mTOR	S-GENE
)	O
,	O
Akt	S-GENE
,	O
and	O
glycogen	B-GENE
synthase	I-GENE
kinase	I-GENE
3beta	E-GENE
(	O
GSK	B-GENE
-	I-GENE
3beta	E-GENE
)	O
signaling	O
pathways	O
was	O
achieved	O
using	O
small	O
-	O
molecule	O
pharmacologic	O
inhibitors	O
.	O


RESULTS	O
:	O
Binding	O
of	O
JunB	S-GENE
to	O
the	O
COL1A2	S-GENE
enhancer	O
was	O
observed	O
,	O
with	O
its	O
coalescence	O
directed	O
by	O
activation	O
of	O
gene	O
transcription	O
through	O
the	O
proximal	O
promoter	O
.	O


Knockdown	O
of	O
JunB	S-GENE
reduced	O
enhancer	O
activation	O
and	O
COL1A2	S-GENE
expression	O
in	O
response	O
to	O
transforming	B-GENE
growth	I-GENE
factor	I-GENE
beta	E-GENE
.	O


In	O
SSc	O
dermal	O
fibroblasts	O
,	O
increased	O
mTOR	S-GENE
/	O
Akt	S-GENE
signaling	O
was	O
associated	O
with	O
inactivation	O
of	O
GSK	B-GENE
-	I-GENE
3beta	E-GENE
,	O
leading	O
to	O
blockade	O
of	O
JunB	S-GENE
degradation	O
and	O
,	O
thus	O
,	O
constitutively	O
high	O
expression	O
of	O
JunB	S-GENE
.	O


CONCLUSION	O
:	O
In	O
patients	O
with	O
SSc	O
,	O
the	O
accumulation	O
of	O
JunB	S-GENE
resulting	O
from	O
altered	O
mTOR	S-GENE
/	O
Akt	S-GENE
signaling	O
and	O
a	O
failure	O
of	O
proteolytic	O
degradation	O
underpins	O
the	O
aberrant	O
overexpression	O
of	O
type	B-GENE
I	I-GENE
collagen	E-GENE
.	O


These	O
findings	O
identify	O
JunB	S-GENE
as	O
a	O
potential	O
target	O
for	O
antifibrotic	O
therapy	O
in	O
SSc	O
.	O
